Teladoc Health Stock Drops 5% As Quarterly Guidance Underwhelms

Tiger Newspress04-26

Digital medical services platform Teladoc Health announced better-than-expected results in Q1 CY2024, with revenue up 2.7% year on year to $646.1 million. On the other hand, next quarter's revenue guidance of $647.5 million was less impressive, coming in 2.3% below analysts' estimates. It made a GAAP loss of $0.49 per share, down from its loss of $0.42 per share in the same quarter last year.

The shares dropped 4.7% in premarket trading Friday.

Teladoc (TDOC) Q1 CY2024 Highlights:

  • Revenue: $646.1 million vs analyst estimates of $637.4 million (1.4% beat)

  • EPS: -$0.49 vs analyst expectations of -$0.47 (3.9% miss)

  • Revenue Guidance for Q2 CY2024 is $647.5 million at the midpoint, below analyst estimates of $662.6 million

  • The company reconfirmed its revenue guidance for the full year of $2.69 billion at the midpoint

  • Gross Margin (GAAP): 69.9%, in line with the same quarter last year

  • Free Cash Flow was -$26.59 million, down from $128.7 million in the previous quarter

  • US Integrated Care Members: 91.8 million, up 6.9 million year on year

  • Market Capitalization: $2.32 billion

Founded to help people in rural areas get online medical consultations, Teladoc Health (NYSE:TDOC) is a telemedicine platform that facilitates remote doctor’s visits.

Online MarketplaceMarketplaces have existed for centuries. Where once it was a main street in a small town or a mall in the suburbs, sellers benefitted from proximity to one another because they could draw customers by offering convenience and selection. Today, a myriad of online marketplaces fulfill that same role, aggregating large customer bases, which attracts commission-paying sellers, generating flywheel scale effects that feed back into further customer acquisition.

Sales GrowthTeladoc's revenue growth over the last three years has been strong, averaging 28.7% annually. This quarter, Teladoc beat analysts' estimates but reported lacklustre 2.7% year-on-year revenue growth.

Teladoc is expecting next quarter's revenue to decline 0.8% year on year to $647.5 million, a reversal from the 10.1% year-on-year increase it recorded in the comparable quarter last year. Ahead of the earnings results, analysts were projecting sales to grow 3% over the next 12 months.

Usage Growth As an online marketplace, Teladoc generates revenue growth by increasing both the number of users on its platform and the average order size in dollars.

Over the last two years, Teladoc's users, a key performance metric for the company, grew 7.8% annually to 91.8 million. This is decent growth for a consumer internet company.

In Q1, Teladoc added 6.9 million users, translating into 8.1% year-on-year growth.

Revenue Per UserAverage revenue per user (ARPU) is a critical metric to track for consumer internet businesses like Teladoc because it measures how much the company earns in transaction fees from each user. Furthermore, ARPU gives us unique insights as it's a function of a user's average order size and Teladoc's take rate, or "cut", on each order.

Teladoc's ARPU growth has been mediocre over the last two years, averaging 2.7%. However, the company's ability to continue increasing prices while growing its users shows they still find value in its platform. This quarter, ARPU declined 5% year on year to $7.04 per user.

Key Takeaways from Teladoc's Q1 Results It was good to see Teladoc narrowly top analysts' revenue and EBITDA expectations this quarter. Although next quarter's revenue guidance was softer than expected, its full-year sales outlook was in line. Furthermore, its full-year free cash flow and U.S. Integrated Care Member estimates beat Wall Street's estimates. Overall, this was a decent quarter for Teladoc. The stock is up 4.2% after reporting and currently trades at $13.89 per share.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment